TherapeuticsMD (TXMD) Free Cash Flow (QoQ) (2010 - 2026)
Analysis
TherapeuticsMD (TXMD) Free Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.48% |
| Mar 31, 2026 | 151.73% |
| Dec 31, 2025 | -62.46% |
| Sep 30, 2025 | 162.20% |
| Jun 30, 2025 | -45.49% |
| Mar 31, 2025 | 4,011.76% |
| Dec 31, 2024 | 123.94% |
| Sep 30, 2024 | -104.89% |
| Jun 30, 2024 | 734.50% |
| Mar 31, 2024 | 96.85% |
| Dec 31, 2023 | -37.01% |
| Sep 30, 2023 | -82.43% |
| Jun 30, 2023 | 66.64% |
| Mar 31, 2023 | -138.55% |
| Dec 31, 2022 | 27.69% |
| Sep 30, 2022 | 185.58% |
| Jun 30, 2022 | -15.55% |
| Mar 31, 2022 | -137.32% |
| Dec 31, 2021 | 225.81% |
| Sep 30, 2021 | -43.58% |